A mevalonate independent pathway for isoprenoid biosynthesis, the so-called DOXP pathway, has been discovered recently and validated as new drug target. Fosmidomycin, a phosphonate that interferes with this pathway through inhibition of DOXP reductiosomerase, represents a promising antimalarial agent. This project aims at the development of alpha-substituted fosmidomycin analogues that are in vitro superior to fosmidomycin in inhibiting the growth of P. falciparum and other pathogens that use the non-mevalonate pathway.